Neurizon Therapeutics Limited has released a press release.
Appendix 3B & s708 Notice
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust Receives Pre-Approval for R&D Tax Rebates
- Epichem Export Business Receives Important WA State Awards
- PharmAust Raises $2.4m in Placement
- Agreement with Uni of Melbourne U-Vet for Phase II Dog Trial
- Phase II Dog Cancer Trial Commences
Later from Neurizon Therapeutics
- Epichem new CEO and Board additions
- AGM Presentation
- Progress in Recruitment for Phase II Trial in Dogs
- Presentation - Pitt Street Research Life Sciences Conference
- Expanded Site Recruitment for Phase II MPL Dog Cancer Trial
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics